Legal Status This site displays a prototype of a “Web 2.0” version of the daily
Federal Register. It is not an official legal edition of the Federal
Register, and does not replace the official print version or the official
electronic version on GPO’s govinfo.gov.

The documents posted on this site are XML renditions of published Federal
Register documents. Each document posted on the site includes a link to the
corresponding official PDF file on govinfo.gov. This prototype edition of the
daily Federal Register on FederalRegister.gov will remain an unofficial
informational resource until the Administrative Committee of the Federal
Register (ACFR) issues a regulation granting it official legal status.
For complete information about, and access to, our official publications
and services, go to About the Federal Register on NARA's archives.gov.

The OFR/GPO partnership is committed to presenting accurate and reliable
regulatory information on FederalRegister.gov with the objective of
establishing the XML-based Federal Register as an ACFR-sanctioned
publication in the future. While every effort has been made to ensure that
the material on FederalRegister.gov is accurately displayed, consistent with
the official SGML-based PDF version on govinfo.gov, those relying on it for
legal research should verify their results against an official edition of
the Federal Register. Until the ACFR grants it official status, the XML
rendition of the daily Federal Register on FederalRegister.gov does not
provide legal notice to the public or judicial notice to the courts.

Legal Status

Rule

Mandatory Guidelines for Federal Workplace Drug Testing Programs-Authorized Testing Panels

A Rule by the Health and Human Services Department on 03/13/2026

• 1.

1.

• Document Details Published Content - Document Details Agency Department of Health and Human Services CFR 42 CFR chapter I Document Citation 91 FR 12308 Document Number 2026-04981 Document Type Rule Pages 12308-12311
  (4 pages) Publication Date 03/13/2026 Published Content - Document Details

• PDF Official Content

  • View printed version (PDF) Official Content

• Document Details Published Content - Document Details Agency Department of Health and Human Services CFR 42 CFR chapter I Document Citation 91 FR 12308 Document Number 2026-04981 Document Type Rule Pages 12308-12311
  (4 pages) Publication Date 03/13/2026 Published Content - Document Details

• Document Dates Published Content - Document Dates Dates Text The current authorized drug testing panels and required report nomenclature remain in effect. Published Content - Document Dates

• Table of Contents Enhanced Content - Table of Contents This table of contents is a navigational tool, processed from the
  headings within the legal text of Federal Register documents.
  This repetition of headings to form internal navigation links
  has no substantive legal effect.

  • AGENCY:
  • ACTION:
  • SUMMARY:
  • DATES:
  • FOR FURTHER INFORMATION CONTACT:
  • SUPPLEMENTARY INFORMATION:
  • Costs and Benefits
  • HHS Biomarker Testing Panel—Urine
  • HHS Biomarker Testing Panel—Oral Fluid Enhanced Content - Table of Contents

• Public Comments Enhanced Content - Public Comments This feature is not available for this document.

Enhanced Content - Public Comments
- Regulations.gov Data Enhanced Content - Regulations.gov Data Additional information is not currently available for this document.

Enhanced Content - Regulations.gov Data

- Sharing Enhanced Content - Sharing Shorter Document URL https://www.federalregister.gov/d/2026-04981 Email Email this document to a friend Enhanced Content - Sharing

• Print Enhanced Content - Print
  • Print this document Enhanced Content - Print
• Other Formats Enhanced Content - Other Formats This document is also available in the following formats:

JSON Normalized attributes and metadata XML Original full text XML MODS Government Publishing Office metadata More information and documentation can be found in our developer tools pages.

Enhanced Content - Other Formats
- Public Inspection Public Inspection This PDF is FR Doc. 2026-04981 as it appeared on Public Inspection on
03/12/2026 at 8:45 am.

It was viewed
68
times while on Public Inspection.

If you are using public inspection listings for legal research, you
should verify the contents of the documents against a final, official
edition of the Federal Register. Only official editions of the
Federal Register provide legal notice of publication to the public and judicial notice
to the courts under 44 U.S.C. 1503 & 1507. Learn more here.

Public Inspection
Published Document: 2026-04981 (91 FR 12308) This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Document Headings Document headings vary by document type but may contain
the following:

1. the agency or agencies that issued and signed a document
2. the number of the CFR title and the number of each part the document amends, proposes to amend, or is directly related to
3. the agency docket number / agency internal file number
4. the RIN which identifies each regulatory action listed in the Unified Agenda of Federal Regulatory and Deregulatory Actions See the Document Drafting Handbook for more details.

Department of Health and Human Services

1. 42 CFR Chapter 1

AGENCY:

Substance Abuse and Mental Health Services Administration (SAMHSA), Department of Health and Human Services (HHS).

ACTION:

Issuance of authorized drug testing panels.

SUMMARY:

HHS herein publishes the panels of Schedule I and II drugs and biomarkers authorized for testing in federal workplace drug testing programs. The Department has made no revisions to the current drug testing panels for both urine and oral fluid and current required nomenclature for laboratory and Medical Review Officer Reports, effective July 7, 2025.

DATES:

The current authorized drug testing panels and required report nomenclature remain in effect.

FOR FURTHER INFORMATION CONTACT:

Eugene D. Hayes, Ph.D., MBA, SAMHSA, Center for Substance Abuse Prevention, Division of Workplace Programs; 5600 Fishers Lane, Room 16N02, Rockville, MD 20857, by telephone (240) 276-1459 or by email at Eugene.Hayes@samhsa.hhs.gov.

SUPPLEMENTARY INFORMATION:

The drug testing panels in this notification specify the analytes and cutoffs for federal agency workplace drug testing specimens and the nomenclature (i.e., analyte names and abbreviations) that

( printed page 12309) must be used to report federal workplace drug test results. There are no changes to the drug testing analytes, test cutoffs, and report nomenclature published in the January 16, 2025, Notification (90 FR 4662). The Department has edited footnotes 1 and 2 in the drug testing panels for clarity and correctness.

This notification is in accordance with Subpart C of the Mandatory Guidelines for Federal Workplace Drug Testing Programs using Urine (UrMG, 88 FR 70768) and the Mandatory Guidelines for Federal Workplace Drug Testing Programs using Oral Fluid (OFMG, 88 FR 70814). Section 3.4 of Subpart C calls upon the Secretary of HHS to “publish the drug and biomarker test analytes and cutoffs (i.e., the drug testing panel' andbiomarker testing panel') for initial and confirmatory drug and biomarker tests in the Federal Register each year,” and make them available on the internet at http://www.samhsa.gov/​workplace. Section 3.4 of the UrMG and the OFMG also requires HHS-certified laboratories, instrumented initial test facilities (IITF, urine only), and Medical Review Officers to use the nomenclature (i.e., analyte names and abbreviations) published with the drug and biomarker testing panels to report federal workplace drug test results.

Costs and Benefits

No analysis is needed because the current drug testing panels and nomenclature tables remain in effect. Currently, the Department does not require HHS-certified test facilities to implement authorized biomarker tests. Each laboratory and IITF should conduct their own cost analysis when deciding whether to offer biomarker testing to federally regulated clients. The Department will consider costs when deciding whether to require all certified test facilities to test for a specific biomarker.

| Urine | |
| --- | |
| Abbreviation | Analyte |
| Δ9THCC | Δ-9-tetrahydrocannabinol-9-carboxylic acid. |
| BZE | Benzoylecgonine. |
| COD | Codeine. |
| MOR | Morphine. |
| HYC | Hydrocodone. |
| HYM | Hydromorphone. |
| OXYC | Oxycodone. |
| OXYM | Oxymorphone. |
| 6-AM | 6-Acetylmorphine. |
| PCP | Phencyclidine. |
| FENT | Fentanyl. |
| NFENT | Norfentanyl. |
| AMP | Amphetamine. |
| MAMP | Methamphetamine. |
| MDMA | Methylenedioxymethamphetamine. |
| MDA | Methylenedioxyamphetamine. |

| HHS Drug Testing Panel—Urine | | | |
| --- | | | |
| Initial test analyte | Initial test

                            cutoff 1 (ng/mL) | Confirmatory test analyte | Confirmatory test cutoff 
                         (ng/mL) |

| Marijuana metabolite (Δ9THCC) | 2 50 | Δ9THCC | 15 |
| Cocaine metabolite (Benzoylecgonine) | 2 150 | Benzoylecgonine | 100 |
| Codeine/Morphine | 2,000 | Codeine | 2,000 |
| | | Morphine | 4,000 |
| Hydrocodone/Hydromorphone | 300 | Hydrocodone | 100 |
| | | Hydromorphone | 100 |
| Oxycodone/Oxymorphone | 100 | Oxycodone | 100 |
| | | Oxymorphone | 100 |
| 6-Acetylmorphine | 10 | 6-Acetylmorphine | 10 |
| Phencyclidine | 25 | Phencyclidine | 25 |
| Fentanyl 3 | 1 | Fentanyl | 1 |
| | | Norfentanyl | 1 |
| Amphetamine/Methamphetamine | 500 | Amphetamine | 250 |
| | | Methamphetamine | 250 |
| MDMA/MDA | 500 | Methylenedioxymethamphetamine | 250 |
| | | Methylenedioxyamphetamine | 250 |
| 1 For grouped analytes (i.e., two or more analytes that are in the same drug class and have the same initial test cutoff): | | | |
| Immunoassay: The test must be calibrated with one analyte from the group identified as the target analyte. The cross-reactivity of the immunoassay to the other analyte(s) within the group must be 80 percent or greater; if not, separate immunoassays must be used for the analytes within the group. ( printed page 12310) | | | |
| Alternate technology: Either one analyte or all analytes from the group must be used for calibration, depending on the technology. For a technology that measures a response from the entire group without differentiating between analytes (e.g., an activity-based assay), the laboratory must compare the result to the initial test cutoff. In the case of an alternate technology that differentiates and quantifies each analyte in the group, the laboratory must compare each analyte's result to the confirmatory test cutoff and reflex specimens with a positive initial test result to confirmatory testing. | | | |
| 2 Alternate technology: When an alternate technology initial test is specific for the target analyte, the confirmatory test cutoff must be used for the initial test (i.e., Δ9THCC, 15 ng/mL; BZE, 100 ng/mL). | | | |
| 3 A fentanyl immunoassay must have at least 5% cross-reactivity to norfentanyl. | | | |

HHS Biomarker Testing Panel—Urine

SAMHSA has not yet authorized routine testing for any biomarker in urine. HHS-certified laboratories and IITFs may request authorization to test federal agency specimens for a biomarker upon Medical Review Officer request by submitting supporting documentation and assay validation records to the National Laboratory Certification Program for SAMHSA review and approval.

| Oral fluid | |
| --- | |
| Abbreviation | Analyte |
| Δ9THC | Δ-9-tetrahydrocannabinol. |
| COC | Cocaine. |
| BZE | Benzoylecgonine. |
| COD | Codeine. |
| MOR | Morphine. |
| HYC | Hydrocodone. |
| HYM | Hydromorphone. |
| OXYC | Oxycodone. |
| OXYM | Oxymorphone. |
| 6-AM | 6-Acetylmorphine. |
| PCP | Phencyclidine. |
| FENT | Fentanyl. |
| AMP | Amphetamine. |
| MAMP | Methamphetamine. |
| MDMA | Methylenedioxymethamphetamine. |
| MDA | Methylenedioxyamphetamine. |

| HHS drug testing panel—undiluted (neat) oral fluid | | | |
| --- | | | |
| Initial test analyte | Initial test

                            cutoff 1 (ng/mL) | Confirmatory test analyte | Confirmatory 
                         test cutoff 
                         (ng/mL) |

| Marijuana (Δ9THC) | 2 4 | Δ9THC | 2 |
| Cocaine/Benzoylecgonine | 15 | Cocaine
Benzoylecgonine | 8
8 |
| Codeine/Morphine | 30 | Codeine
Morphine | 15
15 |
| Hydrocodone/Hydromorphone | 30 | Hydrocodone
Hydromorphone | 15
15 |
| Oxycodone/Oxymorphone | 30 | Oxycodone
Oxymorphone | 15
15 |
| 6-Acetylmorphine | 2 4 | 6-Acetylmorphine | 2 |
| Phencyclidine | 10 | Phencyclidine | 10 |
| Fentanyl | 2 4 | Fentanyl | 1 |
| Amphetamine/Methamphetamine | 50 | Amphetamine
Methamphetamine | 25
25 |
| MDMA/MDA | 50 | Methylenedioxymethamphetamine
Methylenedioxyamphetamine | 25
25 |
| 1 For grouped analytes (i.e., two or more analytes that are in the same drug class and have the same initial test cutoff): | | | |
| Immunoassay: The test must be calibrated with one analyte from the group identified as the target analyte. The cross reactivity of the immunoassay to the other analyte(s) within the group must be 80 percent or greater; if not, separate immunoassays must be used for the analytes within the group. | | | |
| Alternate technology: Either one analyte or all analytes from the group must be used for calibration, depending on the technology. For a technology that measures a response from the entire group without differentiating between analytes (e.g., an activity-based assay), the laboratory must compare the result to the initial test cutoff. In the case of an alternate technology that differentiates and quantifies each analyte in the group, the laboratory must compare each analyte's result to the confirmatory test cutoff and reflex specimens with a positive initial test result to confirmatory testing. | | | |
| 2 Alternate technology: When an alternate technology initial test is specific for the target analyte, the confirmatory test cutoff must be used for the initial test (i.e., Δ9THC, 2 ng/mL; 6-AM, 2 ng/mL; FENT, 1 ng/mL). | | | |
( printed page 12311)

HHS Biomarker Testing Panel—Oral Fluid

SAMHSA has not yet authorized routine testing for any biomarker in oral fluid. HHS-certified laboratories may request authorization to test Federal agency specimens for a biomarker by submitting supporting documentation and assay validation records to the National Laboratory Certification Program for SAMHSA review and approval. Authorized biomarker test cutoffs for oral fluid will be based on undiluted (neat) oral fluid.

Robert F. Kennedy, Jr.,

Secretary, Department of Health and Human Services.

[FR Doc. 2026-04981 Filed 3-12-26; 8:45 am]

BILLING CODE 4162-20-P

Published Document: 2026-04981 (91 FR 12308)